Karyopharm Therapeutics(US:KPTI) Prnewswire·2026-02-12 12:30Core Insights - Karyopharm Therapeutics reported its financial results for Q4 and full year 2025, highlighting significant revenue growth and upcoming clinical milestones for its lead product, XPOVIO (selinexor) [1][2] Financial Performance - Total revenue for Q4 2025 was $34.1 million, up from $30.5 million in Q4 2024, while full-year revenue reached $146.1 million compared to $145.2 million in 2024 [2][5] - U.S. net product revenue for XPOVIO was $32.1 million in Q4 2025, compared to $29.3 million in Q4 2024, and $114.9 million for the full year, up from $112.8 million in 2024 [2][5] - The company expects total revenue for 2026 to be between $130 million and $150 million, with U.S. XPOVIO net product revenue projected between $115 million and $130 million [1][2] Research and Development Highlights - The Phase 3 SENTRY trial for myelofibrosis is expected to report top-line data in March 2026, with the potential to introduce the first combination therapy in this area [1][3] - The Phase 3 XPORT-EC-042 trial for endometrial cancer is on track to report top-line data in mid-2026, focusing on a biomarker-driven patient population [1][3] - Enrollment in the Phase 3 XPORT-MM-031 trial for multiple myeloma was completed in Q4 2024, with top-line data anticipated in the second half of 2026 [1][3] Operational Objectives - The company aims to maintain its commercial foundation in the competitive multiple myeloma market and drive increased revenues for XPOVIO [2][3] - Karyopharm plans to support global launches of XPOVIO in ex-U.S. territories following regulatory approvals [2][3] Market Context - Myelofibrosis affects approximately 20,000 patients in the U.S., with significant unmet needs in treatment options [3] - Endometrial cancer is the most common gynecologic malignancy in the U.S., with rising incidence and mortality rates, highlighting the need for effective therapies [3][4]